

<b>PATENT ASSIGNMENT COVER SHEET</b>
--------------------------------------

Electronic Version v1.1  
 Stylesheet Version v1.2

Assignment ID: PATI716519

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	Security Agreement
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
ICON Clinical Research Limited	12/20/2024
<b>RECEIVING PARTY DATA</b>	
<b>Company Name:</b>	Citibank, N.A., London Branch, as Notes Collateral Agent
<b>Street Address:</b>	6th Floor CGC1
<b>Internal Address:</b>	Citigroup Centre, Canada Square
<b>City:</b>	London
<b>State/Country:</b>	UNITED KINGDOM
<b>Postal Code:</b>	E14 5LB
<b>PROPERTY NUMBERS Total: 3</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	18181733
<b>Application Number:</b>	11383376
<b>Application Number:</b>	11383381
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	8007130755
<b>Email:</b>	Michael.Violet@wolterskluwer.com
<b>Correspondent Name:</b>	Michael Violet
<b>Address Line 1:</b>	4400 Easton Commons Way
<b>Address Line 2:</b>	Suite 125
<b>Address Line 4:</b>	Columbus, OHIO 43219
<b>NAME OF SUBMITTER:</b>	Michael Violet
<b>SIGNATURE:</b>	Michael Violet
<b>DATE SIGNED:</b>	12/24/2024
<b>Total Attachments: 6</b>	
source=ICON - ICON Clinical Research Limited Patent SA Supplement (2021 Notes) (Transfers)#page1.tiff	
source=ICON - ICON Clinical Research Limited Patent SA Supplement (2021 Notes) (Transfers)#page2.tiff	
source=ICON - ICON Clinical Research Limited Patent SA Supplement (2021 Notes) (Transfers)#page3.tiff	

source=ICON - ICON Clinical Research Limited Patent SA Supplement (2021 Notes) (Transfers)#page4.tiff  
source=ICON - ICON Clinical Research Limited Patent SA Supplement (2021 Notes) (Transfers)#page5.tiff  
source=ICON - ICON Clinical Research Limited Patent SA Supplement (2021 Notes) (Transfers)#page6.tiff

## PATENT SECURITY AGREEMENT

This **PATENT SECURITY AGREEMENT**, dated as of December 20, 2024 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, this “**Agreement**”), is made by the entity identified as a grantor on the signature pages hereto (the “**Grantor**”) in favor of Citibank, N.A., London Branch, as collateral agent for the First Lien Notes Secured Parties (in such capacity, together with its successors and permitted assigns, the “**Notes Collateral Agent**”).

**WHEREAS**, reference is made to that certain Indenture, dated as of July 1, 2021 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “**Indenture**”), among Indigo Merger Sub, Inc., a Delaware corporation (as Merger Sub and, prior to the consummation of the Merger, as the Issuer) (which, after giving effect to the Merger on the Closing Date, shall be succeeded by PRA Health Sciences, Inc., a Delaware corporation (as the Target and, following the consummation of the Merger, the Issuer)), ICON public limited company, an Irish public limited company (as the Parent), the other Guarantors (as defined in the Indenture), and Citibank, N.A., London Branch as Trustee and as Notes Collateral Agent;

**NOW, THEREFORE**, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Grantor hereby agrees with the Notes Collateral Agent as follows:

### **SECTION 1. Defined Terms**

Unless otherwise defined herein, terms defined in the Indenture and used herein have the meaning given to them in the Indenture.

### **SECTION 2. Grant of Security Interest in Patent Collateral**

**SECTION 2.1 Grant of Security.** As collateral security for the prompt and complete payment or performance in full when due, whether at stated maturity, by required prepayment, declaration, acceleration, demand or otherwise, of all the First Priority Notes Obligations, the Grantor hereby grants to the Notes Collateral Agent, for the benefit of the First Lien Notes Secured Parties, a security interest in and continuing lien on all of the Grantor’s right, title and interest in, to and under the following, in each case whether now owned or hereafter acquired by the Grantor or in which the Grantor now has or hereafter acquires any right, title or interest and wherever the same may be located (collectively, the “**Patent Collateral**”):

all United States patents, and applications for any of the foregoing, including, without limitation: (i) each patent and patent application listed in **Schedule A** attached hereto, (ii) all reissues, divisions, continuations, continuations-in-part, extensions, renewals and reexaminations thereof and (iii) the right to sue or otherwise recover for any past, present and future infringement or other violation thereof.

**SECTION 2.2 Certain Limited Exclusions.** Notwithstanding anything herein to the contrary, in no event shall the Patent Collateral include or the security interest granted under Section 2.1 hereof attach to any Excluded Assets.

### **SECTION 3. Intercreditor Agreement**

The security interest granted pursuant to this Agreement is granted in conjunction with the Indenture.

Notwithstanding anything herein to the contrary, (i) the liens and security interests granted to the Notes Collateral Agent pursuant to this Agreement are expressly subject to the First Lien Intercreditor Agreement and (ii) the exercise of any right or remedy by the Notes Collateral Agent hereunder is subject to the limitations and provisions of the First Lien Intercreditor Agreement. In the event of any conflict between the terms of the First Lien Intercreditor Agreement and the terms of this Agreement, the terms of the First Lien Intercreditor Agreement shall govern. If any Event of Default is continuing, the Notes Collateral Agent may, but is not obligated to, subject in all respects to the terms of the First Lien Intercreditor Agreement, exercise in respect of the Collateral, in addition to all

other rights and remedies otherwise available to it at law or in equity, all the rights and remedies of a secured party on default under the Uniform Commercial Code.

**SECTION 4. Governing Law**

THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO CONFLICT OF LAWS PRINCIPLES THEREOF.

**SECTION 5. Counterparts**

This Agreement may be executed in one or more counterparts and by different parties hereto in separate counterparts, each of which when so executed and delivered shall be deemed an original, but all such counterparts together shall constitute but one and the same instrument. Delivery of an executed counterpart to this Agreement by facsimile transmission or other electronic transmission (such as .pdf or .tif) shall be effective as delivery of a manually signed counterpart of this Agreement. The words "execution," "signed", "signature" and words of like import herein shall be deemed to include electronic signatures, the electronic matching of assignment terms and contract formations on the electronic platform DocuSign, digital copies of a signatory's manual signature and deliveries or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature to the extent and as provided in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act.

**SECTION 6. Financing Statements**

The Grantor hereby authorizes the Notes Collateral Agent to file financing or continuation statements and amendments and supplements thereto, in any jurisdictions and with any filing offices as the Notes Collateral Agent may determine, in its reasonable discretion, are necessary or advisable to perfect or otherwise protect the security interest granted to the Notes Collateral Agent herein. Such financing statements may describe the Collateral in the same manner as described herein or may contain an indication or description of collateral that describes such property in any other manner reasonably acceptable to the Grantor.

[Remainder of page intentionally left blank]

**IN WITNESS WHEREOF**, the Grantor has caused this Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

**ICON CLINICAL RESEARCH LIMITED**

By:   
Name: Simon Hollywood  
Title: Director

MF

Accepted and Agreed:  
**CITIBANK, N.A., LONDON BRANCH,**  
as Notes Collateral Agent

By:           *L Hughes*          

Name:

Title:

**Laura Hughes**  
**Vice President**

[Signature Page to Patent Security Agreement]

**PATENT**  
**REEL: 069768 FRAME: 0914**

SCHEDULE A  
to  
PATENT SECURITY AGREEMENT

PATENTS AND PATENT APPLICATIONS

<b>Title</b>	<b>Record Owner</b>	<b>App. No.</b>	<b>Filing Date</b>	<b>Patent No.</b>	<b>Issue Date</b>
Systems and methods for provenance and data integrity monitoring	ICON Clinical Research Limited	18181733	10-March-2023	N/A	N/A
Method and apparatus for sequenced extraction from electrocardiogramic waveforms	ICON Clinical Research Limited	11383376	15-May-2006	8055331	11/08/2011
Method and apparatus for rapid interpretive analysis of electrocardiographic waveforms	ICON Clinical Research Limited	11383381	15-May-2006	8543193	09/24/2013